A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients

Luehmann, Natalie; Ascha, Mona; Chwa, Emily S.; Hackenberger, Paige N; Termanini, Kareem; Benning, C. D.; Sama, Danny; Felt, Dylan; Beach, Lauren B.; Gupta, Dipti; Kulkarni, Swati; Jordan, Sumanas W.

doi:10.1245/s10434-021-10932-z

Cited by 31 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these treatments pose a relevant risk for the development of BC, and there are currently no guidelines or defined screening surveillance of breast tissue for MtF, FtM, and sex-nonconforming individuals (Clarke et al ., 2022). An American study observed a lower adherence to BC screening from transgender individuals (Luehmann et al ., 2022). The authors analyzed 253 patients (60 FtM and 193 MtF), and they identified that breast screening adherence rates ranged from 2 to 50% for MtF and 7 to 40% for FtM compared with cisgender individuals, which was estimated in the same study to be around 78%.…”

Section: Discussionmentioning

confidence: 99%

Section: The Incidence Of Breast Cancer In Transgender People Is Lowmentioning

confidence: 99%

See 1 more Smart Citation

Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis

Corso

Gandini

D’Ecclesiis

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Background and aimsThe risk of developing breast cancer in transgender individuals [male-to-female (MtF) or female-to-male (FtM)] is still inadequately quantified. We aimed to evaluate the impact of breast cancer in this population. MethodsWe conducted a systematic literature search and review using the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines through the PUBMED and SCOPUS databases. We identified six cohort studies (for both populations) plus 35 case reports. Incidence and breast cancer risk quantification were the main outcomes considered. ResultsFtM individuals had a higher risk of developing breast cancer in comparison to cisgender men [standardized incidence ratio (SIR) = 63.4; 95% confidence interval (CI), 32.2-124.9] but a lower risk than cisgender women (SIR = 0.42; 95% CI, 0.07-2.41). Similarly, MtF individuals were at higher risk of developing breast cancer in comparison to cisgender men (SIR = 22.5; 95% CI, 5.54-91.8) and at lower risk than cisgender women (SIR = 0.30; 95% CI, 0.22-0.42). ConclusionIn this systematic study and metaanalysis, we identified that FtM and MtF individuals are at substantially higher risk of developing breast cancer in comparison to cisgender men, though at lower risk than cisgender women. These individuals, in the absence of defined guidelines for breast cancer prevention, should periodically undergo breast or chest examinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Incidence Of Breast Cancer In Transgender People Is Lowmentioning

confidence: 99%

Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis

Corso

Gandini

D’Ecclesiis

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…59 Screening guidelines for transgender patients established by the American College of Radiology in 2021 take into account these effects of gender affirming therapies, as well as sex assigned at birth and modifiable risk factors, while acknowledging that their recommendations rely on limited cohort and case studies as well as data extrapolated from research on cisgender individuals. 58 The recency of established guidelines for this population may be one reason for lower breast cancer screening among transgender patients, 60 in addition to the effects of discrimination, stigmatization, and inequitable access to health care. 50,61 Among transgender men who have undergone reduction mammoplasty, screening may also be limited by patient or clinician impression that they are no longer at risk of breast cancer, although top surgery does not fully remove all breast tissue as in oncologic mastectomy.…”

Section: While Factors That Contribute To Oncologic Disparities Inmentioning

confidence: 99%

Surgical Implications of LGBTQ+ Health Disparities: A Review

Awe

2022

The American Surgeon

View full text Add to dashboard Cite

Lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ+) patients face challenging health care disparities. However, due to restrictions in reporting and collection of sexual orientation and gender identity (SOGI) demographic data, comprehensive studies of surgical disparities in the LGBTQ+ population are limited. This review aims to summarize the existing literature describing surgical disparities in LGBTQ+ patients and to identify areas of surgical care in which further studies are warranted. This review addresses the literature in infectious diseases, substance use disorders, bariatrics, cardiovascular medicine, oncology, and laryngology as relevant to surgical practice. Understanding the current landscape of knowledge in LGBTQ+ surgical disparities and the areas where gaps in research exist will help the surgeon to create a framework of practice to provide more equitable care to LGBTQ+ patients.

show abstract

“…TGD people face numerous healthcare-related disparities, such as higher rates of uninsurance and unequal access to preventive healthcare screenings, including lower rates of cancer screenings. [9][10][11] Furthermore, more than a quarter of TGD patients report delayed medical care due to past discrimination, and half report having to teach their healthcare providers about how to render healthcare to TGD individuals. 10 Such disparities translate into poorer health outcomes, including higher rates of cancer-specific mortality from non-Hodgkin lymphoma and prostate and bladder cancers.…”

mentioning

confidence: 99%

Understanding Disparities: A Case Illustrative of the Struggles Facing Transgender and Gender Diverse Patients With Cancer

Cathcart-Rake¹,

Kling²,

Carroll³

et al. 2023

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

and the National Institutes of Health have all recognized transgender and gender diverse (TGD) individuals as medically underserved and in need of clinical research aimed at the successful delivery of equitable healthcare. [1][2][3][4][5] Improving the poorer cancer outcomes among TGD individuals is important. The first step to mitigating these disparities is identifying TGD people in the electronic health record (EHR) and discussing individual needs and preferences at the point of care. The cancer-specific needs of TGD people and the challenges of identifying these needs to adequately address them are noteworthy, 2,3 as highlighted in the following case.A 48-year-old nonbinary person with no contributory medical or family history was diagnosed with a locally advanced, estrogen receptor-positive, progesterone receptor-negative, HER2-negative breast cancer. The patient elected to pursue bilateral mastectomy without reconstruction, an axillary lymph node dissection, and then adjuvant chemotherapy and endocrine therapy. ELIZABETH J. CATHCART-RAKE, MDElizabeth J. Cathcart-Rake, MD, is medical oncologist at Mayo Clinic with a clinical specialty in treating breast/chest cancer. She aims to improve care for LGBTQIA+ folks with and at risk for cancer through clinical care and research.

show abstract

A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients

Cited by 31 publications

References 33 publications

Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis

Risk and incidence of breast cancer in transgender individuals: a systematic review and meta-analysis

Surgical Implications of LGBTQ+ Health Disparities: A Review

Understanding Disparities: A Case Illustrative of the Struggles Facing Transgender and Gender Diverse Patients With Cancer

Contact Info

Product

Resources

About